Table 1. Effect of a seven-day, twice daily, oral T-705 and ribavirin combination treatment initiated on day 5 of PICV infection in hamsters.
| Disease parameterb | |||||||
| Mean weight | Mean virus titerc±SD | ||||||
| Treatment | Dosage/kg/day | Surv/total | Day 28 (g) | MDDa±SD | Liver | Serum | ALTd±SD |
| T-705+Ribavirin | 50 mg+30 mg | 5/10 | 142 | 24.0±3.5*** | 5.8±1.1 (100)** | <3.7±1.5 (100)** | 30±21** |
| T-705+Ribavirin | 10 mg+30 mg | 5/10 | 113 | 21.2±2.2*** | 6.8±0.6 (100)** | 5.0±0.9 (100)** | 27±29** |
| T-705+Ribavirin | 0 mg+30 mg | 6/10* | 104 | 22.0±3.6*** | 6.9±0.9 (100)** | 4.8±1.2 (100)** | 23±29** |
| T-705+Ribavirin | 50 mg+6 mg | 8/10** | 131 | 14.5±9.2 | 6.7±1.2 (100)** | <3.9±1.3 (80)** | 239±226** |
| T-705+Ribavirin | 10 mg+6 mg | 2/10 | 108 | 12.8±5.7* | 6.8±1.3 (100)** | <5.1±1.8 (100)** | 420±486 ** |
| T-705+Ribavirin | 0 mg+6 mg | 5/10 | 96 | 11.6±5.3 | 8.1±0.5 (100)* | >7.3±0.9 (100) | 794±441** |
| T-705+Ribavirin | 50 mg+0 mg | 3/10 | 148 | 14.1±5.1** | >8.4±0.8 (100) | >6.6±1.6 (100)* | 1460±1308 |
| T-705+Ribavirin | 10 mg+0 mg | 1/10 | 142 | 8.9±0.9 | >8.8±1.2 (100) | >8.2±0.4 (100) | 2678±1833 |
| T-705+Ribavirin | 0 mg+0 mg | 4/20 | 120 | 8.8±1.6 | >9.2±0.4 (100) | >8.2±0.4 (100) | 2517±605 |
| T-705 | 100 mg | 10/10*** | 134 | >28 | 5.6±0.8 (100)** | <3.6±1.8 (80)** | 256±252** |
| Ribavirin | 60 mg | 10/10*** | 113 | >28 | 6.3±0.9 (100)** | <4.5±1.7 (100)** | 16±7** |
| Sham-infected | - | 4/4 | 168 | >28 | <2.8 (0) | <1.8 (0) | 33±10 |
a
Mean day of death of hamsters dying prior to day 28.
b
Determined on day 7 of infection; 5 hamsters per treatment group.
c
Log10 cell culture 50% infectious dose (CCID50)/g of liver or ml of serum. Percentage of animals presenting with detectable virus levels are indicated in parenthesis.
d
Alanine aminotransferase; measured in international units per liter.
*
P<0.05; **P<0.01; ***P<0.001 compared to 0.4% CMC placebo-treated hamsters.